Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Olema Oncology
< Previous
1
2
Next >
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 09, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
August 21, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences in June
May 28, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
May 15, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
May 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences in May
May 01, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
April 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
March 06, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
February 06, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
January 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
December 05, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
November 28, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences in November
November 01, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
October 22, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright